EBMT 2021 | The importance of common language for CAR-T

Name: The importance of common language for CAR-T
Uploaded: 2021-03-18T00:00:00Z
Duration: 57 s
Description: Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the importance of having a common language for clinical research investigating chimeric antigen receptor T-cell (CAR-T) therapy in order to enable trial results to be compared. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Stephan Grupp • 18 Mar 2021

EBMT 2021

General CAR-T

Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the importance of having a common language for clinical research investigating chimeric antigen receptor T-cell (CAR-T) therapy in order to enable trial results to be compared. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Disclosures

Dr Stephan Grupp, MD, PhD, has received research support from Novartis, Servier, Vertex and Kite; and has participated in study steering committees, consulting, or scientific advisory boards with Novartis, Allogene, Adaptimmune, TCR2, Cabaletta, Juno, CBMG, GlaxoSmithKline, Cellectis, Johnson & Johnson/Janssen, CRISPR/Vertex, Roche, Humanigen and Jazz.